{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:09Z","timestamp":1787009409086,"version":"build-2736575974"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FI20\/00020"],"award-info":[{"award-number":["FI20\/00020"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017266","name":"Gobierno de Navarra","doi-asserted-by":"publisher","award":["FPU21\/00603"],"award-info":[{"award-number":["FPU21\/00603"]}],"id":[{"id":"10.13039\/501100017266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["817884"],"award-info":[{"award-number":["817884"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pediatric high-grade gliomas (pHGGs), including diffuse midline gliomas (DMGs), are aggressive pediatric tumors with one of the poorest prognoses. Delta-24-RGD and ONC201 have shown promising efficacy as single agents for these tumors. However, the combination of both agents has not been evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The production of functional viruses was assessed by immunoblotting and replication assays. The antitumor effect was evaluated in a panel of human and murine pHGG and DMG cell lines. RNAseq, the seahorse stress test, mitochondrial DNA content, and \u03b3H2A.X immunofluorescence were used to perform mechanistic studies. Mouse models of both diseases were used to assess the efficacy of the combination in vivo. The tumor immune microenvironment was evaluated using flow cytometry, RNAseq, and multiplexed immunofluorescence staining.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The Delta-24-RGD\/ONC201 combination did not affect the virus replication capability in human pHGG and DMG models in vitro. Cytotoxicity analysis showed that the combination treatment was either synergistic or additive. Mechanistically, the combination treatment increased nuclear DNA damage and maintained the metabolic perturbation and mitochondrial damage caused by each agent alone. Delta-24-RGD\/ONC201 cotreatment extended the overall survival of mice implanted with human and murine pHGG and DMG cells, independent of H3 mutation status and location. Finally, combination treatment in murine DMG models revealed a reshaping of the tumor microenvironment to a proinflammatory phenotype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The Delta-24-RGD\/ONC201 combination improved the efficacy compared to each agent alone in in vitro and in vivo models by potentiating nuclear DNA damage and in turn improving the antitumor (immune) response to each agent alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noae066","type":"journal-article","created":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T06:27:42Z","timestamp":1711780062000},"page":"1509-1525","source":"Crossref","is-referenced-by-count":13,"title":["The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0626-0711","authenticated-orcid":false,"given":"Daniel","family":"de la Nava","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Cl\u00ednica Universidad de Navarra , Pamplona , Spain"},{"name":"Solid Tumor Program, Center for the Applied Medical Research , Pamplona , Spain"},{"name":"Health Research Institute of Navarra (IdiSNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0590-6579","authenticated-orcid":false,"given":"Iker","family":"Ausejo-Mauleon","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cl\u00ednica Universidad de Navarra , Pamplona , Spain"},{"name":"Solid Tumor Program, Center for the Applied Medical Research , Pamplona , Spain"},{"name":"Health Research Institute of Navarra (IdiSNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6017-7295","authenticated-orcid":false,"given":"Virginia","family":"Laspidea","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cl\u00ednica Universidad de Navarra , Pamplona , Spain"},{"name":"Solid Tumor Program, Center for the Applied Medical Research , Pamplona , Spain"},{"name":"Health Research Institute of Navarra (IdiSNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Gonzalez-Huarriz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cl\u00ednica Universidad de Navarra , Pamplona , Spain"},{"name":"Solid Tumor Program, Center for the Applied Medical Research , Pamplona , Spain"},{"name":"Health Research Institute of Navarra (IdiSNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lacalle","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cl\u00ednica Universidad de Navarra , Pamplona , Spain"},{"name":"Solid Tumor Program, Center for the Applied Medical Research , Pamplona , Spain"},{"name":"Health Research Institute of Navarra (IdiSNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Casares","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cl\u00ednica Universidad de Navarra , Pamplona , Spain"},{"name":"Solid Tumor Program, Center for the Applied Medical Research , Pamplona , Spain"},{"name":"Health Research Institute of Navarra (IdiSNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Zalacain","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cl\u00ednica Universidad de Navarra , Pamplona , Spain"},{"name":"Solid Tumor Program, Center for the Applied Medical Research , Pamplona , Spain"},{"name":"Health Research Institute of Navarra (IdiSNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Marrodan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cl\u00ednica Universidad de Navarra , Pamplona , Spain"},{"name":"Solid Tumor Program, Center for the Applied Medical Research , Pamplona , Spain"},{"name":"Health Research Institute of Navarra (IdiSNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Garc\u00eda-Moure","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"},{"name":"Department of Pediatrics, Cl\u00ednica Universidad de Navarra , Pamplona , Spain"},{"name":"Solid Tumor Program, Center for the Applied Medical Research , Pamplona , Spain"},{"name":"Health Research Institute of Navarra (IdiSNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C","family":"Ochoa","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cl\u00ednica Universidad de Navarra , Pamplona , Spain"},{"name":"Solid Tumor Program, Center for the Applied Medical Research , Pamplona , Spain"},{"name":"Health Research Institute of Navarra (IdiSNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Carlos","family":"Tallon-Cobos","sequence":"additional","affiliation":[{"name":"Solid Tumor Program, Center for the Applied Medical Research , Pamplona , Spain"},{"name":"Health Research Institute of Navarra (IdiSNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyes","family":"Hernandez-Osuna","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cl\u00ednica Universidad de Navarra , Pamplona , Spain"},{"name":"Solid Tumor Program, Center for the Applied Medical Research , Pamplona , Spain"},{"name":"Health Research Institute of Navarra (IdiSNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Marco-Sanz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cl\u00ednica Universidad de Navarra , Pamplona , Spain"},{"name":"Solid Tumor Program, Center for the Applied Medical Research , Pamplona , Spain"},{"name":"Health Research Institute of Navarra (IdiSNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laasya","family":"Dhandapani","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cl\u00ednica Universidad de Navarra , Pamplona , Spain"},{"name":"Solid Tumor Program, Center for the Applied Medical Research , Pamplona , Spain"},{"name":"Health Research Institute of Navarra (IdiSNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irati","family":"Herv\u00e1s-Corpi\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cl\u00ednica Universidad de Navarra , Pamplona , Spain"},{"name":"Solid Tumor Program, Center for the Applied Medical Research , Pamplona , Spain"},{"name":"Health Research Institute of Navarra (IdiSNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oren J","family":"Becher","sequence":"additional","affiliation":[{"name":"Jack Martin Fund Division of Pediatric Hematology-oncology , Mount Sinai, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1951-9828","authenticated-orcid":false,"given":"Javad","family":"Nazarian","sequence":"additional","affiliation":[{"name":"Division of Oncology and Children\u2019s Research Center, DIPG\/DMG Research Center Zurich, University Children\u2019s Hospital Zurich , Zurich , Switzerland"},{"name":"Virginia Tech University , Washington, District of Columbia , USA"},{"name":"Children\u2019s National Health System, Center for Genetic Medicine Research , Washington, District of Columbia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Mueller","sequence":"additional","affiliation":[{"name":"University of California, San Francisco San Francisco, California , USA"},{"name":"Division of Oncology and Children\u2019s Research Center, DIPG\/DMG Research Center Zurich, University Children\u2019s Hospital Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy N","family":"Phoenix","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati , Cincinnati, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"van der Lugt","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology , Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikel","family":"Hernaez","sequence":"additional","affiliation":[{"name":"Bioinformatics Platform, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona , Spain"},{"name":"Health Research Institute of Navarra (IdiSNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Guruceaga","sequence":"additional","affiliation":[{"name":"Bioinformatics Platform, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona , Spain"},{"name":"Health Research Institute of Navarra (IdiSNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0825-7615","authenticated-orcid":false,"given":"Carl","family":"Koschmann","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Michigan , Ann Arbor, Michigan , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriram","family":"Venneti","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Michigan , Ann Arbor, Michigan , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua E","family":"Allen","sequence":"additional","affiliation":[{"name":"Chimerix, Inc. Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9063-5370","authenticated-orcid":false,"given":"Matthew D","family":"Dun","sequence":"additional","affiliation":[{"name":"Paediatric Stream, Mark Hughes Foundation Centre for Brain Cancer Research, College of Health, Medicine, and Wellbeing , Callaghan, New South Wales , Australia"},{"name":"Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights , New South Wales , Australia"},{"name":"Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, New South Wales , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Fueyo","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candelaria","family":"Gomez-Manzano","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Gallego Perez-Larraya","sequence":"additional","affiliation":[{"name":"Department of Neurology, Cl\u00ednica Universidad de Navarra , Pamplona , Spain"},{"name":"Solid Tumor Program, Center for the Applied Medical Research , Pamplona , Spain"},{"name":"Health Research Institute of Navarra (IdiSNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pati\u00f1o-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cl\u00ednica Universidad de Navarra , Pamplona , Spain"},{"name":"Solid Tumor Program, Center for the Applied Medical Research , Pamplona , Spain"},{"name":"Health Research Institute of Navarra (IdiSNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Labiano","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cl\u00ednica Universidad de Navarra , Pamplona , Spain"},{"name":"Solid Tumor Program, Center for the Applied Medical Research , Pamplona , Spain"},{"name":"Health Research Institute of Navarra (IdiSNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7520-7351","authenticated-orcid":false,"given":"Marta M","family":"Alonso","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cl\u00ednica Universidad de Navarra , Pamplona , Spain"},{"name":"Solid Tumor Program, Center for the Applied Medical Research , Pamplona , Spain"},{"name":"Health Research Institute of Navarra (IdiSNA) , Pamplona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,30]]},"reference":[{"issue":"5","key":"2024080523533232300_CIT0001","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"issue":"9","key":"2024080523533232300_CIT0002","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/neuonc\/nox107","article-title":"Contemporary survival endpoints: An international diffuse intrinsic pontine glioma registry study","volume":"19","author":"Cooney","year":"2017","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024080523533232300_CIT0003","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11060-017-2701-8","article-title":"Survival outcomes in pediatric recurrent high-grade glioma: Results of a 20-year systematic review and meta-analysis","volume":"137","author":"Kline","year":"2018","journal-title":"J Neurooncol."},{"issue":"2","key":"2024080523533232300_CIT0004","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1158\/2159-8290.CD-21-1094","article-title":"A summary of the inaugural WHO classification of pediatric tumors: Transitioning from the optical into the molecular era","volume":"12","author":"Pfister","year":"2022","journal-title":"Cancer Discov"},{"issue":"4","key":"2024080523533232300_CIT0005","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"issue":"2","key":"2024080523533232300_CIT0006","first-page":"153","article-title":"Pediatric high-grade glioma: Biologically and clinically in need of new thinking","volume":"19","author":"Jones","year":"2017","journal-title":"Neuro Oncol"},{"issue":"9","key":"2024080523533232300_CIT0007","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrclinonc.2011.95","article-title":"Challenging issues in pediatric oncology","volume":"8","author":"Pui","year":"2011","journal-title":"Nat Rev Clin Oncol."},{"issue":"9","key":"2024080523533232300_CIT0008","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41582-022-00679-w","article-title":"Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours","volume":"18","author":"Horbinski","year":"2022","journal-title":"Nat Rev Neurol."},{"issue":"19","key":"2024080523533232300_CIT0009","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2017.75.9308","article-title":"Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A collaborative report from the International and European Society for Pediatric Oncology DIPG registries","volume":"36","author":"Hoffman","year":"2018","journal-title":"J Clin Oncol."},{"issue":"8","key":"2024080523533232300_CIT0010","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/neuonc\/noad031","article-title":"Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics\u2014CheckMate 908","volume":"25","author":"Dunkel","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024080523533232300_CIT0011","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","article-title":"Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: Preliminary first-in-human bioactivity and safety","volume":"13","author":"Vitanza","year":"2023","journal-title":"Cancer Discov"},{"issue":"7903","key":"2024080523533232300_CIT0012","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature."},{"issue":"26","key":"2024080523533232300_CIT0013","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","article-title":"Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma","volume":"386","author":"G\u00e1llego P\u00e9rez-Larraya","year":"2022","journal-title":"N Engl J Med."},{"issue":"17","key":"2024080523533232300_CIT0014","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","article-title":"Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas","volume":"384","author":"Friedman","year":"2021","journal-title":"N Engl J Med."},{"issue":"9","key":"2024080523533232300_CIT0015","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: A new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov."},{"issue":"1","key":"2024080523533232300_CIT0016","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41467-019-10043-0","article-title":"The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models","volume":"10","author":"Mart\u00ednez-V\u00e9lez","year":"2019","journal-title":"Nat Commun."},{"issue":"1","key":"2024080523533232300_CIT0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40478-019-0714-6","article-title":"Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models","volume":"7","author":"Martinez-Velez","year":"2019","journal-title":"Acta Neuropathol Commun"},{"issue":"14","key":"2024080523533232300_CIT0018","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (delta-24-RGD) oncolytic adenovirus: Replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J Clin Oncol."},{"issue":"6","key":"2024080523533232300_CIT0019","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat Med."},{"issue":"6","key":"2024080523533232300_CIT0020","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1158\/1078-0432.CCR-20-3313","article-title":"Delta-24-RGD, an oncolytic adenovirus, increases survival and promotes proinflammatory immune landscape remodeling in models of AT\/RT and CNS-PNET","volume":"27","author":"Garcia-Moure","year":"2021","journal-title":"Clin Cancer Res."},{"issue":"9","key":"2024080523533232300_CIT0021","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/95.9.652","article-title":"Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway","volume":"95","author":"Fueyo","year":"2003","journal-title":"J Natl Cancer Inst."},{"key":"2024080523533232300_CIT0022","first-page":"noad144","article-title":"A review of the anti-tumor potential of current therapeutics targeting the mitochondrial protease ClpP in H3K27-altered, diffuse midline glioma","author":"Jackson","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024080523533232300_CIT0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-12928-6","article-title":"A Bayesian machine learning approach for drug target identification using diverse data types","volume":"10","author":"Madhukar","year":"2019","journal-title":"Nat Commun."},{"issue":"9","key":"2024080523533232300_CIT0024","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1093\/neuonc\/noac041","article-title":"Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas","volume":"24","author":"Przystal","year":"2022","journal-title":"Neuro Oncol"},{"issue":"5","key":"2024080523533232300_CIT0025","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ccell.2019.03.014","article-title":"Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality","volume":"35","author":"Ishizawa","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"2024080523533232300_CIT0026","first-page":"1","article-title":"Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma","volume":"3","author":"Duchatel","year":"2021","journal-title":"Neuro Oncol Adv."},{"issue":"11","key":"2024080523533232300_CIT0027","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1158\/2159-8290.CD-23-0131","article-title":"Clinical efficacy of ONC201 in H3K27M- mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways","volume":"13","author":"Venneti","year":"2023","journal-title":"Cancer Discov"},{"issue":"415","key":"2024080523533232300_CIT0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scisignal.aac4374","article-title":"ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2a kinases","volume":"9","author":"Kline","year":"2016","journal-title":"Sci Signal"},{"issue":"415","key":"2024080523533232300_CIT0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scisignal.aac4380","article-title":"ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies","volume":"9","author":"Ishizawa","year":"2016","journal-title":"Sci Signal"},{"issue":"6","key":"2024080523533232300_CIT0030","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1172\/JCI96711","article-title":"Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment","volume":"128","author":"Wagner","year":"2018","journal-title":"J Clin Invest."},{"issue":"1","key":"2024080523533232300_CIT0031","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/neuonc\/noz164","article-title":"Biological activity of weekly ONC201 in adult recurrent glioblastoma patients","volume":"22","author":"Arrillaga-Romany","year":"2020","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024080523533232300_CIT0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0599-8","article-title":"Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration","volume":"7","author":"Stein","year":"2019","journal-title":"J ImmunoTher Cancer."},{"issue":"3","key":"2024080523533232300_CIT0033","doi-asserted-by":"crossref","first-page":"e0118926","DOI":"10.1371\/journal.pone.0118926","article-title":"A high-throughput in Vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent","volume":"10","author":"Halvorson","year":"2015","journal-title":"PLoS One."},{"issue":"10","key":"2024080523533232300_CIT0034","doi-asserted-by":"crossref","first-page":"e77639","DOI":"10.1371\/journal.pone.0077639","article-title":"PD-0332991, a CDK4\/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma","volume":"8","author":"Barton","year":"2013","journal-title":"PLoS One."},{"issue":"1","key":"2024080523533232300_CIT0035","first-page":"1","article-title":"Generation of immunocompetent syngeneic allograft mouse models for pediatric diffuse midline glioma","volume":"4","author":"Du Chatinier","year":"2022","journal-title":"Neuro Oncol Adv."},{"issue":"W1","key":"2024080523533232300_CIT0036","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: An interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"2024080523533232300_CIT0037","first-page":"OF1","article-title":"ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma","author":"Jackson","year":"2023","journal-title":"Cancer Res."},{"issue":"7","key":"2024080523533232300_CIT0038","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/neuonc\/noab300","article-title":"Dual IGF1R\/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant","volume":"24","author":"De Billy","year":"2022","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024080523533232300_CIT0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40478-022-01381-0","article-title":"Convergent evolution and multi-wave clonal invasion in H3 K27-altered diffuse midline gliomas treated with a PDGFR inhibitor","volume":"10","author":"Arunachalam","year":"2022","journal-title":"Acta Neuropathol Commun"},{"issue":"9","key":"2024080523533232300_CIT0040","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1128\/JVI.02540-10","article-title":"Adenovirus core protein VII protects the viral genome from a DNA damage response at early times after infection","volume":"85","author":"Karen","year":"2011","journal-title":"J Virol."},{"issue":"4","key":"2024080523533232300_CIT0041","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0168-1702(89)90026-9","article-title":"Restricted replication of human adenovirus type 5 in mouse cell lines","volume":"14","author":"Blair","year":"1989","journal-title":"Virus Res."},{"issue":"9","key":"2024080523533232300_CIT0042","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1158\/0008-5472.CAN-06-4180","article-title":"CD133+ and CD133- glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles","volume":"67","author":"Beier","year":"2007","journal-title":"Cancer Res."},{"issue":"6","key":"2024080523533232300_CIT0043","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1128\/MCB.01375-08","article-title":"Convergent functional genomics of oligodendrocyte differentiation identifies multiple autoinhibitory signaling circuits","volume":"29","author":"Pescini Gobert","year":"2009","journal-title":"Mol Cell Biol."},{"issue":"6","key":"2024080523533232300_CIT0044","doi-asserted-by":"crossref","first-page":"e20731","DOI":"10.1371\/journal.pone.0020731","article-title":"Helios is associated with CD4 T cells differentiating to T helper 2 and follicular helper T cells in vivo independently of Foxp3 expression","volume":"6","author":"Serre","year":"2011","journal-title":"PLoS One."},{"issue":"3","key":"2024080523533232300_CIT0045","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/bioinformatics\/btab711","article-title":"ImmuCellAI-mouse: A tool for comprehensive prediction of mouse immune cell abundance and immune microenvironment depiction","volume":"38","author":"Miao","year":"2022","journal-title":"Bioinformatics."},{"issue":"10","key":"2024080523533232300_CIT0046","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/neuonc\/nor092","article-title":"Treatment of high-grade glioma in children and adolescents","volume":"13","author":"MacDonald","year":"2011","journal-title":"Neuro Oncol"},{"key":"2024080523533232300_CIT0047","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.radonc.2021.05.027","article-title":"Effects of the DRD2\/3 antagonist ONC201 and radiation in glioblastoma","volume":"161","author":"He","year":"2021","journal-title":"Radiother Oncol."},{"issue":"1","key":"2024080523533232300_CIT0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-018-0671-0","article-title":"Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms","volume":"37","author":"Wagner","year":"2018","journal-title":"J Exp Clin Cancer Res."},{"issue":"2","key":"2024080523533232300_CIT0049","first-page":"729","article-title":"Preclinical studies with ONC201\/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC)","volume":"12","author":"Liguori","year":"2022","journal-title":"Am J Cancer Res"},{"issue":"4","key":"2024080523533232300_CIT0050","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/15384101.2017.1403689","article-title":"Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies","volume":"17","author":"Prabhu","year":"2018","journal-title":"Cell Cycle"},{"key":"2024080523533232300_CIT0051","first-page":"307","article-title":"Synergistic activity of ABT-263 and ONC201\/TIC10 against solid tumor cell lines is associated with suppression of anti-apoptotic Mcl-1, BAG3, pAkt, and upregulation of pro-apoptotic Noxa and Bax cleavage during apoptosis","volume-title":"Am J Cancer Res","author":"Di Cristofano","year":"2023"},{"issue":"9","key":"2024080523533232300_CIT0052","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1158\/1078-0432.CCR-21-4030","article-title":"Phase II Study of ONC201 in neuroendocrine tumors including pheochromocytoma-paraganglioma and desmoplastic small round cell tumor","volume":"28","author":"Anderson","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"15","key":"2024080523533232300_CIT0053","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1158\/1078-0432.CCR-16-2658","article-title":"First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors","volume":"23","author":"Stein","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2024080523533232300_CIT0054","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/eji.202048957","article-title":"Metabolic and inflammatory reprogramming of macrophages by ONC201 translates in a pro-inflammatory environment even in presence of glioblastoma cells","volume":"51","author":"Gei\u00df","year":"2021","journal-title":"Eur J Immunol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noae066\/57420152\/noae066.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/26\/8\/1509\/58740046\/noae066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/26\/8\/1509\/58740046\/noae066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T19:55:40Z","timestamp":1722887740000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/26\/8\/1509\/7637845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,30]]},"references-count":54,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,3,30]]},"published-print":{"date-parts":[[2024,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noae066","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,3,30]]}}}